Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Valero Energy Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Valero Energy Corporation trades at $330.25 (market cap $93.27B). The key difference: Valero Energy Corporation is far larger — about 3.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Valero Energy Corporation pays a 1.48% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VLO | |
|---|---|---|
Market Cap | $29.60B | $93.27B |
Sector | Health | Energy |
52-Week High | $491.22 | $323.92 |
52-Week Low | $205.48 | $133.38 |
Enterprise Value | $27.56B | $96.74B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Valero Energy (VLO) trades at $329.99, up 4.78% on the day, reflecting strong momentum after recent earnings beats. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals indicate robust profitability with a 29.31% ROE and a P/E of 13.51. Recent news highlights refining strength and geopolitical factors benefiting the sector.
Outlook remains positive with analyst consensus favoring a Buy rating and a $324.27 price target. Key risks include volatile oil prices and refining margin pressures, but disciplined capital allocation and renewable diesel growth offer upside potential for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
